Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.56 |
| ▸ | DHFR | P00374 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | VCAM1 | P19320 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3031212 | 0.83 | MAPT (0.63) | MAPTDHFRSMN1; SMN2VCAM1ALDH1A1 | |
| SCHEMBL5992360 | 0.82 | VCAM1 (0.60) | MAPTDHFRVCAM1ALDH1A1MEN1 | |
| SCHEMBL27631548 | 0.80 | ALDH1A1 (0.51) | MAPTSMN1; SMN2VCAM1ALDH1A1MEN1 | |
| SCHEMBL1025712 | 0.80 | MAPT (0.59) | MAPTSMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL2461199 | 0.80 | VCAM1 (0.58) | MAPTDHFRVCAM1ALDH1A1MEN1 | |
| SCHEMBL10663504 | 0.78 | MAPT (0.66) | MAPTDHFRVCAM1ALDH1A1MEN1 | |
| SCHEMBL9566530 | 0.78 | DHFR (0.60) | MAPTDHFRVCAM1ALDH1A1MEN1 | |
| SCHEMBL1897629 | 0.77 | CRHBP (0.58) | MAPTDHFRVCAM1ALDH1A1MEN1 | |
| SCHEMBL11715625 | 0.77 | DHFR (0.50) | MAPTDHFRSMN1; SMN2VCAM1ALDH1A1 | |
| SCHEMBL28156927 | 0.77 | AAK1 (0.52) | MAPTSMN1; SMN2ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102656164-A | Pyrimidine compounds as tuberculosis inhibitors | VERTEX PHARMA | 2012-09-05 | — | — | CN | disclosed |
| US-20090203692-A1 | NOVEL CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2009-08-13 | — | — | US | disclosed |
| EP-1885362-A2 | NOVEL CHEMICAL COMPOUNDS | Smithkline Beecham Corporation (US) | 2008-02-13 | — | — | EP | disclosed |
| WO-2006127458-A2 | NOVEL CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-11-30 | — | — | WO | disclosed |
| CN-1678321-A | Methods of treating or preventing autoimmune diseases with 2, 4-pyrimidinediamine compounds | RIGEL PHARMACEUTICALS INC (US) | 2005-10-05 | — | — | CN | disclosed |
| CN-1146566-C | 2-aryl-8-oxodihydropurine derivatives, process for producting same, medicinal conty. same, and intermediates thereof | �ձ���ҩ��ʽ���� | 2004-04-21 | — | — | CN | disclosed |
| CN-1094929-C | Acetamide derivative, process for preparing the same, and pharmaceutical composition containing the same | DAINIPPON PHARMACEUTICAL CO (JP) | 2002-11-27 | — | — | CN | disclosed |
| CN-1284076-A | 2-aryl-8-oxodihydropurine derivatives, process for producting same, medicinal conty. same, and intermediates thereof | DAINIPPON PHARMACEUTICAL CO (JP) | 2001-02-14 | — | — | CN | disclosed |
| CN-1186487-A | Acetamide derivatives, process for producing the same, and medicinal composition containing the same | DAINIPPON PHARMACEUTICAL CO (JP) | 1998-07-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203692-A1 | NOVEL CHEMICAL COMPOUNDS | HIPK3, HIPK1, HIPK4 | MAPT 1880/4885DHFR 4595/4885SMN1; SMN2 2437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.